https://doi.org/10.1007/s10549-020-05940-8
W
Wen‐Jia Zuo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
43
Papers
628
Citations
14
h-index
15
i10-index
Wen‐Jia Zuo is an academic researcher from Shanghai Medical College of Fudan University. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & Breast Cancer Treatment Studies. The author has an h-index of 14, co-authored 37 publications.
Papers by this author
worksRandomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
2020 · Breast Cancer Research and Treatment · 6 citations
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
2024 · British Journal of Cancer · 5 citations
https://doi.org/10.1038/s41416-024-02751-2
Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial
2025 · Cancer Letters · 2 citations
https://doi.org/10.1016/j.canlet.2025.217785
Additional file 2: Figure S1. of Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer
2016 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.3600557_d2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat